Cayman TNO155

TNO155 is an orally bioavailable allosteric inhibitor of Src homology region 2 domain-containing phosphatase 2 (SHP-2; IC₅₀ = 0.011 µM). It is selective for SHP-2 over a panel of 52 kinases and phosphatases (IC₅₀s = >10 µM for all). TNO155 decreases phosphorylation of ERK in, and inhibits proliferation of, KYSE-520 human esophageal cancer cells (IC₅₀s = 0.011 and 0.1 µM, respectively). It acts synergistically with dabrafenib (Item No. ) and trametinib (Item No. ) to inhibit proliferation of B-RAF^V600E-expressing HT-29, RKO, and MDST8 colorectal cancer cells. TNO155 (2.5, 10, and 20 mg/kg twice per day) reduces tumor growth in a KYSE-520 mouse xenograft model.

WARNING This product is not for human or veterinary use.